Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

The degenerative disc disease market is witnessing a paradigm shift, transitioning from traditional symptom-focused treatments and surgical procedures toward regenerative and disease-modifying therapies. Emerging pipeline candidates, including SB-01 (Spine Biopharma), IDCT (DiscGenics),...